Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242797 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL26722446 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL12699779 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL4189941 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL90804 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL8825950 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL13447 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL166482 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL14621027 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 | |
| SCHEMBL937629 | 1.00 | MBTD1 (0.44) | MBTD1L3MBTL3EPAS1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10982337-B2 | Corrosion inhibition | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2021-04-20 | — | — | US | disclosed |
| US-20180312980-A1 | CORROSION INHIBITION | SCHLUMBERGER TECHNOLOGY CORPORATION | 2018-11-01 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-9585885-B2 | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9585885-B2 | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160058757-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMA CO LTD (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20150315183-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150315183-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2930175-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIVATIVE AND COMPOSITION | Kissei Pharmaceutical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| WO-2014092006-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIVATIVE AND COMPOSITION | キッセイ薬品工業株式会社 (JP) | 2014-06-19 | — | — | WO | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| WO-2007146136-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315183-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION | DRD2, DRD1, ADRA1D | MBTD1 2306/4885L3MBTL3 4456/4885EPAS1 3307/4885 |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN1, KCNN3, KCNN2 | MBTD1 4073/4885L3MBTL3 4649/4885EPAS1 2191/4885 |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | MBTD1 3621/4885L3MBTL3 502/4885EPAS1 2394/4885 |
| US-20160058757-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | MBTD1 3754/4885L3MBTL3 810/4885EPAS1 2157/4885 |
| US-20180312980-A1 | CORROSION INHIBITION | AOC2, CA1, MAOB | MBTD1 3595/4885L3MBTL3 3327/4885EPAS1 4129/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | MBTD1 2637/4885L3MBTL3 465/4885EPAS1 1994/4885 |
| US-10982337-B2 | Corrosion inhibition | AOC2, CA1, MAOB | MBTD1 3595/4885L3MBTL3 3327/4885EPAS1 4129/4885 |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | MBTD1 4113/4885L3MBTL3 4655/4885EPAS1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.